{
    "nctId": "NCT06471205",
    "briefTitle": "A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer",
    "officialTitle": "A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody Combination Therapy in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. Age: \u226518 years old and \u226475 years old;\n3. Expected survival time \u22653 months;\n4. ECOG 0 or 1;\n5. Subjects with histologically and/or cytologically confirmed, inoperable locally advanced or recurrent or metastatic triple-negative breast cancer;\n6. Patients should not have received previous systemic therapy for unresectable, locally advanced, recurrent, or metastatic triple-negative breast cancer;\n7. A archived tumor tissue specimen or fresh tissue specimen of the primary or metastatic lesion within 2 years must be provided;\n8. Must have at least one place in accordance with RECIST v1.1 define measurable lesions;\n9. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before screening, and the organ function level must meet the requirements;\n10. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. ADC drugs that have received topoisomerase I inhibitors as small molecule toxins;\n2. Palliative radiotherapy within 2 weeks before the first dose;\n3. Patients with checkpoint inhibitors prior to neoadjuvant/adjuvant chemotherapy;\n4. Use of an immunomodulatory drug within 14 days before the first dose of study drug;\n5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;\n6. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n7. Active autoimmune and inflammatory diseases;\n8. Receiving long-term systemic corticosteroid therapy, etc., before the first dose;\n9. Other malignant tumors that progressed or required treatment within 5 years before the first dose;\n10. Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;\n11. Present grade \u22652 radiation pneumonitis according to the RTOG/EORTC definition; Patients with current ILD;\n12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;\n13. 6 months prior to screening needs treatment intervention unstable thrombotic events;\n14. Patients with active central nervous system metastases;\n15. Patients with massive or symptomatic effusions or poorly controlled effusions;\n16. Allergic history to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;\n17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;\n18. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;\n19. Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;\n20. Participated in another clinical trial within 4 weeks before the first dose;\n21. Patients with superior vena cava syndrome should not be rehydrated;\n22. Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;\n23. Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;\n24. Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;\n25. Clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n26. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;\n27. Other circumstances considered by the investigator to be inappropriate for participation in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}